| DC47407 |
Antimalarial agent 3
|
Antimalarial agent 3 shows nanomolar antiplasmodial activity (IC50 = 0.035 μM) and has a very high selectivity index with respect to mammalian cells. |
| DC47406 |
Antileishmanial agent-2
|
Antileishmanial agent-2 shows submicromolar antileishmanial activity (IC50 = 0.29 μM) and a very high selectivity index with respect to mammalian cells. |
| DC47405 |
Antimalarial agent 2
|
Antimalarial agent 2 is a novel orally efficacious antimalarials that suggests a fast in vitro killing profile. |
| DC47404 |
TCMDC-125431
|
TCMDC-125431 is a novel disruptor of the malaria parasite calcium dynamics but minimally inhibits heme crystallization. |
| DC47403 |
TCMDC-136230
|
TCMDC-136230 is a novel disruptor of the malaria parasite calcium dynamics but minimally inhibits heme crystallization. |
| DC47402 |
TCMDC-125457
|
TCMDC-125457 is potent in inducing calcium redistribution but minimally inhibits heme crystallization. TCMDC-125457 demonstrated high efficacy when pulsed in a single-dose combination with artesunate against tightly synchronized artemisinin-resistant ring-stage parasites. |
| DC47401 |
Antileishmanial agent-1
|
Antileishmanial agent-1 exhibits the activity against L. amazonensis promastigotes (IC50 = 15.52 μM) and intracellular amastigotes (IC50 = 4.10 μM). |
| DC47400 |
BRD5018
|
BRD5018 is an antimalarial agent. |
| DC47399 |
MMV674850
|
MMV674850 is potent against asexual stage parasites at 2.7 and 4.5 nM and preferentially targets early-stage gametocytes (early-stage gametocyte: IC50 4.5 ± 3.6 nM; late-stage gametocyte: IC50 28.7 ± 0.2 nM). |
| DC47398 |
MMV666810
|
MMV666810, a 2-aminopyrazine similar to MMV390048, is potent against asexual parasites at 5.94 nM, but against gametocytes, it has a 3.3-fold selectivity to late-stage gametocytes compared to earlier stages (early-stage gametocyte: IC50 603 ± 88 nM; late-stage gametocyte: IC50 179 ± 8 nM). |
